compounded semaglutide fda enforcement 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Troubling Findings in Study of

Many people describe this as the "turning point" where they realize the medication is actually working, even if the scale has not moved dramatically

These infusions can complement oral or hormonal treatments for anxiety and depression and often work much faster

On the other hand, SGLT-2is causes early benefit on heart failure than GLP-1RAs, shows improved hemodynamics and sympathetic inhibition, and is frequently applied for treatment of T2D patients with higher risks of progression to severe heart failure

GLP-1 only affects hunger Theres a false impression that GLP-1 therapies only affect physical hunger cues and meal volume